SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2760)6/6/2012 11:56:31 AM
From: DewDiligence_on_SI  Respond to of 3202
 
>Dew pointed out that the de facto standard monotherapy Humira dose is twice a week rather than weekly as used in this trial in accordance with their label.<

De facto monotherapy is weekly rather than bi-weekly, but the essential point is the same: Humira patients in the ADACTA study were under-dosed.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News